PharmaTher Holdings Ltd. (PHRRF)
USD 0.15
(1.67%)
USD 0.15
(1.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -3.11 Million CAD | 51.45% |
| 2023 | -6.41 Million CAD | -59.98% |
| 2022 | -4.01 Million CAD | -250.54% |
| 2021 | 2.66 Million CAD | 11286.58% |
| 2020 | -23.81 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.33 Million CAD | 16.37% |
| 2024 Q4 | -360.59 Thousand CAD | 0.6% |
| 2024 Q3 | -362.76 Thousand CAD | 65.74% |
| 2024 Q2 | -1.05 Million CAD | 20.57% |
| 2023 Q1 | -1.78 Million CAD | -3020.26% |
| 2023 FY | -6.41 Million CAD | -59.98% |
| 2023 Q4 | -1.59 Million CAD | -111.4% |
| 2023 Q3 | -754.04 Thousand CAD | 66.93% |
| 2023 Q2 | -2.27 Million CAD | -27.49% |
| 2022 Q4 | 61.23 Thousand CAD | 102.03% |
| 2022 Q3 | -3.02 Million CAD | -2103.34% |
| 2022 Q2 | -137.07 Thousand CAD | 85.01% |
| 2022 Q1 | -914.47 Thousand CAD | -1570.55% |
| 2022 FY | -4.01 Million CAD | -250.54% |
| 2021 Q4 | 62.18 Thousand CAD | -98.64% |
| 2021 FY | 2.66 Million CAD | 11286.58% |
| 2021 Q3 | 4.57 Million CAD | 492.45% |
| 2021 Q2 | -1.16 Million CAD | -16.06% |
| 2021 Q1 | -1 Million CAD | 0.0% |
| 2020 FY | -23.81 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -3.81 Million USD | 18.425% |
| Skye Bioscience, Inc. | -37.64 Million USD | 91.724% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 104.783% |
| Nascent Biotech, Inc. | -2.08 Million USD | -49.225% |
| Qrons Inc. | -789.34 Thousand USD | -294.673% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 63.275% |
| CSL Limited | 2.64 Billion USD | 100.118% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 105.88% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 55.386% |
| Regen BioPharma, Inc. | 1.02 Million USD | 404.379% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 95.023% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -649.819% |
| Rebus Holdings, Inc. | -1.02 Million USD | -205.425% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -133.283% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -392.616% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 80.371% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 95.844% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 52.626% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1039.472% |
| SQZ Biotechnologies Company | -79.46 Million USD | 96.08% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -7.708% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -71.123% |
| Mesoblast Limited | -87.95 Million USD | 96.458% |
| Marizyme, Inc. | -65.34 Million USD | 95.233% |
| Genus plc | 7.9 Million USD | 139.435% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 71.397% |
| Pharming Group N.V. | -10.54 Million USD | 70.465% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -43.576% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 16.034% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 64.775% |
| ContraFect Corporation | -65.15 Million USD | 95.218% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 36.24% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -80.343% |
| IMV Inc. | -36.48 Million USD | 91.461% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 61.347% |
| MultiCell Technologies, Inc. | -380.07 USD | -819575.323% |
| ONE Bio Corp. | 8.67 Million USD | 135.905% |
| Accustem Sciences Inc. | -3.74 Million USD | 16.845% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 93.973% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -145.857% |
| Q BioMed Inc. | -2.05 Million USD | -51.813% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 16.546% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -30.849% |
| Biomind Labs Inc. | -1.21 Million USD | -156.55% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 94.784% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -0.438% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 60.581% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -59.823% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -20702.217% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 46.447% |
| GB Sciences, Inc. | -1.36 Million USD | -128.787% |
| Alpha Cognition Inc. | -13.77 Million USD | 77.38% |
| HST Global, Inc. | -146.21 Thousand USD | -2030.73% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -77.535% |
| Halberd Corporation | -79.67 Thousand USD | -3810.011% |
| Enzolytics Inc. | -2.17 Million USD | -43.113% |
| Agentix Corp. | -1.37 Million USD | -126.7% |
| Resverlogix Corp. | -3.61 Million USD | 13.702% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 1.769% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.944% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3278.918% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 144.989% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 21.587% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -2.948% |
| AVAX Technologies, Inc. | -6.41 Million USD | 51.426% |
| Zenith Capital Corp. | -10.59 Million USD | 70.599% |
| Genscript Biotech Corporation | -95.47 Million USD | 96.737% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -13303.924% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 24.858% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -5054.382% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -55.37% |
| Kadimastem Ltd | -3.3 Million USD | 5.807% |
| Helix BioMedix, Inc. | -1.05 Million USD | -194.997% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -605.836% |
| LadRx Corporation | 400.44 Thousand USD | 877.973% |
| Cell Source, Inc. | -5.32 Million USD | 41.454% |
| Regen BioPharma, Inc. | 1.02 Million USD | 404.379% |
| NovAccess Global Inc. | -4.76 Million USD | 34.678% |
| Affymax, Inc. | -14.42 Million USD | 78.402% |
| Itoco Inc. | -1.86 Million USD | -66.685% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 29.875% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -86.659% |
| Mobile Lads Corp. | -2.26 Million USD | -37.646% |
| CytoDyn Inc. | -49.84 Million USD | 93.749% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -3841.822% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1265.617% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -230.881% |
| SYBLEU INC | -180.3 Thousand USD | -1627.826% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -93.171% |
| International Stem Cell Corporation | -131 Thousand USD | -2278.122% |
| Bioxytran, Inc. | -4.28 Million USD | 27.212% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -5640.234% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -23.124% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 93.519% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -47.367% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -298.949% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 1.662% |
| Neutra Corp. | -233.46 Thousand USD | -1234.393% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 84.647% |
| PureTech Health plc | -65.69 Million USD | 95.258% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 85.351% |
| IXICO plc | -1.17 Million USD | -164.46% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 68.618% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 94.547% |
| CSL Limited | 2.64 Billion USD | 100.118% |
| Cellectis S.A. | -103.17 Million USD | 96.98% |